Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.48 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | CASR | P41180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL800515 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL781357 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL29876183 | 1.00 | IDO1 (0.48) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL780403 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| Bromide SCHEMBL28591637 | 0.98 | IDO1 (0.47) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL1239204 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| Iodide SCHEMBL29040444 | 0.98 | IDO1 (0.47) | IDO1TDO2AOC3ACHEHDAC4 | |
| Hydrochloric Acid SCHEMBL507110 | 0.98 | IDO1 (0.52) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL31020152 | 0.85 | IDO1 (0.44) | IDO1TDO2AOC3ACHEHDAC4 | |
| SCHEMBL659099 | 0.83 | ADRB2 (0.46) | SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120049017-A | Org/ZnSO4Electrolyte, preparation method thereof and application of electrolyte in secondary battery | 同济大学 | 2025-05-27 | — | — | CN | claimed |
| CN-114420852-B | Preparation method of pure-phase RP perovskite film | 河北工业大学 | 2025-05-27 | — | — | CN | claimed |
| CN-120004697-A | Preparation method of OrgVO material and application of OrgVO material as secondary battery anode material | 同济大学 | 2025-05-16 | — | — | CN | claimed |
| CN-119726348-A | Near-infrared perovskite laser and preparation method thereof | 中国科学院半导体研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-119726347-A | Non-external-cavity near-infrared perovskite laser and preparation method thereof | 中国科学院半导体研究所 | 2025-03-28 | — | — | CN | claimed |
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-119371337-A | Metal halide perovskite nanocrystalline resistant to heat-induced fluorescence quenching, and preparation method and application thereof | 华南理工大学 | 2025-01-28 | — | — | CN | claimed |
| CN-118507836-B | Electrolyte for secondary lithium metal battery | 深圳欣界能源科技有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-118531558-A | Mixed-dimension perovskite nanofiber membrane with high fluorescence stability and preparation method thereof | 武汉纺织大学 | 2024-08-23 | — | — | CN | claimed |
| CN-118531514-A | Mixed-dimension perovskite/polymer composite filament, preparation method and application | 武汉纺织大学 | 2024-08-23 | — | — | CN | claimed |
| US-20090148921-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. (US) | 2009-06-11 | — | — | US | claimed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | claimed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | claimed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | claimed |
| EP-1590666-B1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2008-07-09 | — | — | EP | claimed |
| EP-1590666-A4 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH INC (US) | 2006-07-26 | — | — | EP | claimed |
| EP-1590666-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | Genentech, Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| US-20040171554-A1 | Compositions and methods for enhancing apoptosis | GENENTECH, INC. | 2004-09-02 | — | — | US | claimed |
| WO-2004072641-A1 | COMPOSITIONS AND METHODS FOR ENHANCING APOPTOSIS | GENENTECH, INC. (US) | 2004-08-26 | — | — | WO | claimed |
| US-4209638-A | RESOLUTION OF ENANTIOMORPHS | THE BOOTS COMPANY LIMITED (GB) | 1980-06-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | IDO1 481/4885TDO2 311/4885AOC3 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.